發(fā)布時(shí)間:
2022
-
03
-
11
點(diǎn)擊次數(shù):
0
所屬職位：
執(zhí)行總監(jiān)、全球藥物研發(fā)中國(guó)綜合科學(xué)團(tuán)隊(duì)負(fù)責(zé)人
所屬公司：
百時(shí)美施貴寶
個(gè)人簡(jiǎn)介：
邊峰博士是百時(shí)美施貴寶全球藥物研發(fā)中國(guó)綜合科學(xué)團(tuán)隊(duì)執(zhí)行總監(jiān), 常駐上海。她負(fù)責(zé)中國(guó)針對(duì)早期研發(fā)的外部合作，主要關(guān)注中國(guó)以及周邊亞洲地區(qū)的創(chuàng)新性科學(xué)進(jìn)展包括新靶點(diǎn)，突破性技術(shù)，新型有效或高度差異化的臨床前分子和療法，轉(zhuǎn)化醫(yī)學(xué)，并負(fù)責(zé)與生命科學(xué)領(lǐng)域建立密切的合作關(guān)系。之前她是輝瑞Emerging Science & Innovation (ES&I)高級(jí)總監(jiān)/中國(guó)新興科學(xué)與創(chuàng)新合作負(fù)責(zé)人。在加入輝瑞之前，邊峰博士自2014年起在中國(guó)諾華生物醫(yī)學(xué)研究中心擔(dān)任高級(jí)研究員和肝臟疾病臨床前藥理學(xué)平臺(tái)負(fù)責(zé)人。在諾華公司，她是項(xiàng)目負(fù)責(zé)人并管理肝病藥理學(xué)平臺(tái)，為中國(guó)和全球藥物研發(fā)項(xiàng)目提供臨床前藥理數(shù)據(jù)。在諾華之前，她于2012年加入強(qiáng)生公司，是在上海參與建立生物研究實(shí)驗(yàn)室的關(guān)鍵科學(xué)家。在強(qiáng)生公司，她擔(dān)任生物學(xué)副總監(jiān)，參與管理CRO，學(xué)術(shù)研究合作以及內(nèi)部研發(fā)項(xiàng)目。 邊博士的研發(fā)生涯起始于美國(guó)Parke-Davis / Warner-Lambert公司，擔(dān)任神經(jīng)科學(xué)部門的臨床前體內(nèi)藥理學(xué)家，后來成為輝瑞公司在美國(guó)的全球研發(fā)總部神經(jīng)科學(xué)部門的首席科學(xué)家，為L(zhǎng)yrica®等項(xiàng)目做出貢獻(xiàn)。她還參與阿爾茨海默病，抑郁癥和皮膚纖維化等疾病的創(chuàng)新藥物研究。邊博士在小分子和生物藥物研究方面擁有20多年的專業(yè)知識(shí)，她的工作支持多個(gè)創(chuàng)新藥物項(xiàng)目進(jìn)入人體實(shí)驗(yàn)階段。邊博士在俄亥俄州立大學(xué)獲得生物化學(xué)博士學(xué)位，并在天津南開大學(xué)獲得理學(xué)學(xué)士學(xué)位。Dr. Feng Bian is an Executive Director of Integrative Sciences/China R&D at Bristol Myers Squibb based in Shanghai. She is responsible for scouting and partnering in early R&D space to cultivate strong and in-depth scientific relationships with academic and life science communities with a primary focus on China and nearby regions to access emerging sciences including novel targets, breakthrough technologies, new or highly differentiated preclinical assets, and translation research.Before this, Dr. Bian was a Senior Director and China Emerging Science Lead in Pfizer Emerging Science & Innovation (ES&I) of Pfizer Worldwide Research, Development & Medical focusing on China and nearby Asia regions. Prior to Pfizer ES&I, Dr. Bian was a senior investigator in China Novartis Institutes for Biomedical Research and group head of liver pharmacology since 2014 in Shanghai. At Novartis, she was a project leader and managed liver disease pharmacology platform to deliver data packages for worldwide drug discovery projects. Before Novartis, she was a key scientist participated in setting up JnJ China research labs in 2012, and Associate Director of Biology to manage CROs and academic collaborations as well as internal R&D programs. Dr. Bian began her R&D career in Parke-Davis/Warner-Lambert in US as an in vivo pharmacologist in the Neuroscience Division, and later became a principal scientist in Pfizer’s Neurodegeneration and Psychotherapeutics Unit, contributing to programs like Lyrica®, discovery programs for Alzheimer’s disease, bipolar depression and dermal fibrosis. Dr. Bian has more than 20 years of expertise in small molecule and biologics drug discovery and her work has enabled several NMEs to reach first in human. Dr. Bian received her Doctorate degree in Biochemistry from The Ohio State University and her Bachelor of Science degree from Nankai University at Tianjin, China.